drugset

drugset / Trial / NCT02815748

The Metabolite Identification and Material Balance Study of SP2086

NCT02815748 ↗

Phase 1 Completed 8 enrolled Jiangsu HengRui Medicine Co., Ltd.

NaSingle-groupOpen-labelTreatment

Summary

The purpose of the study is to investigate the Metabolite identification and material balance of SP2086 in healthy adult volunteers.

Timeline

Start: 2015-08
Primary completion: 2015-10
Completion: 2015-10

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Retagliptin	Small molecule	100 mg	—

Indications